SCHEMBL14111

SCHEMBL14111

NCCCNCc1ccc(-n2cc3cc(CC4CCCCC4)[nH]c3nc2=O)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 10/20 0.34
CXCL12 P48061 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
ROCK2 O75116 3/20 0.33
MC4R P32245 1/20 0.33
MC5R P33032 1/20 0.33
MC3R P41968 1/20 0.33
KIT P10721 1/20 0.33
CHRNB2 P17787 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
CHRNA4 P43681 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2A Q12879 1/20 0.32
GRM1 Q13255 1/20 0.32
HDAC3 O15379 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13808 0.91 SIGMAR1 (0.37) CXCR4CXCL12SIGMAR1ROCK2MC4R
SCHEMBL13822 0.85 MC4R (0.38) MC4RMC5RMC3RHDAC3HDAC4
SCHEMBL12075420 0.84 MC4R (0.38) MC4RMC5RMC3RHDAC3HDAC4
SCHEMBL12075768 0.84 MC4R (0.38) MC4RMC5RMC3RHDAC3HDAC4
SCHEMBL14287 0.81 MC4R (0.36) MC4RMC5RMC3R
SCHEMBL12061576 0.81 MC4R (0.40) MC4RMC5RMC3RHDAC3HDAC4
SCHEMBL14451 0.81 MC4R (0.36) MC4RMC5RMC3RHDAC6OPRM1
SCHEMBL13738 0.81 CXCR4 (0.36) CXCR4CXCL12ROCK2MC4RMC5R
SCHEMBL14116 0.80 MC4R (0.35) MC4RMC5RMC3ROPRM1OPRK1
SCHEMBL12061703 0.80 ROCK2 (0.34) ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME BioVersys AG (CH) 2016-02-04 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
WO-2011047319-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same MPO, LPO, CAT CXCR4 2740/4885CXCL12 3437/4885SIGMAR1 3381/4885
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MPO, LPO, CAT CXCR4 2740/4885CXCL12 3437/4885SIGMAR1 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.